Background: One of the hallmarks of the psoriatic plaque is increased epidermal proliferation. Whether this is the result of an increased recruitment of cycling epidermal cells or a decrease in cell cycle time has been a matter of debate for years. Objective: Calculating cell-kinetic information from the number of S phase cells in psoriasis by in situ hybridisation using a histone probe and the number of cycling epidermal cells by immunohistochemistry using the MIB-1 antibody. Methods: Immunohistochemistry and non-isotopic in situ hybridisation were performed on serial sections of 33 untreated psoriatic samples and 14 tacalcitol-treated samples. Results: The labelling index (number of cells in S phase/number cycling cells per millimetre length of section) in psoriatic untreated as well as in treated plaques is 16%. The amount of S phase cells in our experiment is equal compared with the number of cells in S phase as determined by BrdU incorporation. Conclusion: Using this direct approach to study cell-kinetic behaviour of psoriatic skin, we reconfirm that the psoriatic abnormality is due to a defect in the G₀–G1 recruitment mechanism (by increased recruitment of G₀ cells), a decrease in apoptosis or an increase in the number of cell divisions in the transit-amplifying compartment, rather than a reduction in the cell cycle time.

Keywords:
Psoriasis, Tacalcitol, Cell cycle time, S phase, Labelling index
1.
Weinstein GD, McCullough JL, Ross PA: Cell kinetic basis for pathophysiology of psoriasis. J Invest Dermatol 1985;85:579–583.
2.
Gelfant S: The cell cycle in psoriasis: A reappraisal. Br J Dermatol 1976;95:577–590.
3.
Heenen M, Galand P: The growth fraction of normal human epidermis. Dermatology 1997;194:313–317.
4.
Wrone Smith T, Johnson T, Nelson B, Boise LH, Thompson CB, Nunez G, Nickoloff BJ: Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995;146:1079–1088.
5.
Yu CC, Woods AL, Levison DA: The assessment of cellular proliferation by immunohistochemistry: A review of currently available methods and their applications. Histochem J 1992;24:121–131.
6.
Hall PA, Levison DA: Review: Assessment of cell proliferation in histological material. J Clin Pathol 1990;43:184–192.
7.
Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357–363.
8.
Sawhney N, Hall PA: Ki67 – Structure, function, and new antibodies. J Pathol 1992;168:161–162.
9.
Epstein WL, Maibach HI: Cell renewal in human epidermis. Arch Dermatol 1965;92:462–468.
10.
Berlingin E, Heenen M, Galand P: Measurement of S-phase duration in human epidermis using cyclin immunostaining and 3H-thymidine pulse labelling. Arch Dermatol Res 1992;284:238–241.
11.
Gratzner HG: Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 1982;218:474–475.
12.
van Erp PEJ, de Mare S, Rijzewijk JJ, van de Kerkhof PCM, Bauer FW: A sequential double immunoenzymic staining procedure to obtain cell kinetic information in normal and hyperproliferative epidermis. Histochem J 1989;21:343–347.
13.
Alison M, Chaudry Z, Baker J, Lauder I, Pringle H: Liver regeneration: A comparison of in situ hybridization for histone mRNA with bromodeoxyuridine labeling for the detection of S-phase cells. J Histochem Cytochem 1994;42:1603–1608.
14.
Smith MD, Healy E, Thompson V, Morley A, Rees JL: Use of in situ detection of histone mRNA in the assessment of epidermal proliferation: Comparison with the Ki-67 antigen and BrdU incorporation. Br J Dermatol 1995;132:359–366.
15.
Peters DC, Balfour JA: Tacalcitol. Drugs 1997;54:265–271.
16.
Castelijns FACM, Gerritsen MJP, van Vlijmen-Willems IMJJ, van Erp PEJ, van de Kerkhof PCM: The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis. J Am Acad Dermatol 1999;40:901–909.
17.
Castelijns FACM, Ezendam J, Latijnhouwers MAHE, van Vlijmen-Willems IMJJ, Zeeuwen PLJM, Gerritsen MJP, van de Kerkhof PCM, van Erp PEJ: Epidermal cell kinetics by combining in situ hybridization and immunohistochemistry. Histochem J 1998;39:869–877.
18.
Smith MD, Healy E, Thompson V, Morley A, Rees JL: Use of in situ detection of histone mRNA in the assessment of epidermal proliferation: Comparison with the Ki-67 antigen and BrdU incorporation. Br J Dermatol 1995;132:359–366.
19.
Castelijns FACM, Gerritsen MJP, van Vlijmen-Willems IMJJ, van Erp PEJ, van de Kerkhof PCM: Proliferation is the main epidermal target in the treatment of psoriasis plaques with once daily application of tacalcitol ointment. Acta Dermatol Venereol 1999;79:111–114.
20.
Castelijns FACM, Gerritsen MJP, van Erp PEJ, van de Kerkhof PCM: Efficacy of calcipotriol ointment applied under hydrocolloid occlusion in psoriasis. Dermatology 2000;200:25–30.
21.
Kuijpers ALA, van Pelt JPA, Bergers M, Boegheim PJ, Den Bakker JE, Siegenthaler G, van de Kerkhof PCM, Schalkwijk J: The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Br J Dermatol 1998;139:380–389.
22.
van der Vleuten CJM, de Jong EMG, van de Kerkhof PCM: Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol Res 1996;288:366–372.
23.
van der Vleuten CJM, de Jong EMG, van de Kerkhof PCM: Epidermal differentiation characteristics of the psoriatic plaque during short contact treatment with dithranol cream. Clin Exp Dermatol 1996;21:409–414.
24.
van der Vleuten CJM, van Vlijmen-Willems IMJJ, de Jong EMG, van de Kerkhof PCM: Clobetasol-17-propionate under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-proprionate ointment twice daily in psoriasis: An immunohistochemical study on remission and relapse. Arch Dermatol Res 1999;291:390–395.
25.
van Pelt JPA, de Jong EMG, de Bakker ESM, van de Kerkhof PCM: Effects of systemic treatment with liarozole on cutaneous inflammation, epidermal proliferation and differentiation in extensive plaque psoriasis. Skin Pharmacol Appl Skin Physiol 1998;11:70–79.
26.
de Jong EMG, van de Kerkhof PCM: Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: Modulations and interrelations. Br J Dermatol 1991;124:221–229.
27.
de Jong EMG, Ferrier CM, de Zwart A, Wauben Penris PJ, Korstanje C, van de Kerkhof PCM: Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 1995;9:185–194.
28.
Rijzewijk JJ, Groenendal H, van Erp PEJ, Bauer FW, van Vloten WA: Cell kinetics in skin disorders with disturbed keratinization. Acta Dermatol Venereol 1992;72:256–258.
29.
Heenen M, Thiriar S, Noel J-C, Galand P: Ki-67 immunostaining of normal human epidermis: Comparison with 3H-thymidine labelling and PCNA immunostaining. Dermatology 1998;197:123–126.
30.
Hatta N, Takata M, Kawara S, Hirone T, Takehara K: Tape stripping induces marked epidermal proliferation and altered TGF-alpha expression in non-lesional psoriatic skin. J Dermatol Sci 1997;14:154–161.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.